Cancer Immunol Immunother: Camrelizumab in combination with apatinib and S1 as second-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma

Current second-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma is still suboptimal
.

Anti-PD-1 monoclonal antibody combined with anti- angiogenic therapy has anti-tumor activity and synergistic effect

Current second-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma is still suboptimal

In this open-label, single-arm, phase II trial (NCT04345783), eligible patients received combination therapy (camrelizumab 200 mg IV d1, apatinib 500 mg po bid d1-d21, S- 1 Based on body surface area dose po d1-d14, q21d), until the trial is stopped, the disease progresses, and intolerable toxicity occurs
.

or withdraw consent

In this open-label, single-arm, phase II trial (NCT04345783), eligible patients received combination therapy (camrelizumab 200 mg IV d1, apatinib 500 mg po bid d1-d21, S- 1 Based on body surface area dose po d1-d14, q21d), until the trial is stopped, the disease progresses, and intolerable toxicity occurs

Between May 2019 and August 2020, we enrolled a total of 24 patients in this trial

The median duration of response (mDOR) in patients with CR or PR reached 6.
86 weeks (95% CI 6.
12-7.
60)
.

The median duration of response (mDOR) in patients with CR or PR reached 6.
86 weeks (95% CI 6.
12-7.
60)
.

The median duration of response (mDOR) in patients with CR or PR reached 6.

The median progression-free survival was 6.
5 months (95%CI 6.
01-6.
99), and the median overall survival was not reached (95%CI 10.
3–NA)
.

The 6-month overall survival rate was 75.

The median progression-free survival was 6.

In exploratory analysis, of 19 patients with complete genetic profile, 9 (47.
4%) had PD-L1 CPS ≥1, 10 (52.
6%) had PD-L1 CPS <1; 1 (5.
3%) The patients had complete remission, 5 (26.
3%) patients had partial remission, and 12 (63.
2%) patients had stable disease
.

The overall objective efficacy was 31.

In exploratory analysis, of 19 patients with complete genetic profile, 9 (47.

At data cutoff, patients with PD-L1 CPS ≥1 had a median PFS of 6.
20 (95%CI 4.
94-7.
46) months and patients with PD-L1 CPS <1 had a median PFS of 6.
53 (95%CI 6.
47-6.
60) months month (HR: 1.
94, 95%CI 0.
43 to 8.
79, P=0.
391)
.

Median PFS was not reached in patients with high TMB (95% CI 4 0-not reached), and median PFS in patients with low TMB was 6.
50 months (95% CI 5.
78-7.
23) (HR: 0.
451, 95%CI 0.
090- 2.
263)
.

At data cutoff, patients with PD-L1 CPS ≥1 had a median PFS of 6.
20 (95%CI 4.
94-7.
46) months and patients with PD-L1 CPS <1 had a median PFS of 6.
53 (95%CI 6.
47-6.
60) months month (HR: 1.
94, 95%CI 0.
43 to 8.
79, P=0.
391)
.
Median PFS was not reached in patients with high TMB (95% CI 4 0-not reached), and median PFS in patients with low TMB was 6.
50 months (95% CI 5.
78-7.
23) (HR: 0.
451, 95%CI 0.
090- 2.
263)
.
At data cutoff, patients with PD-L1 CPS ≥1 had a median PFS of 6.
20 (95%CI 4.
94-7.
46) months and patients with PD-L1 CPS <1 had a median PFS of 6.
53 (95%CI 6.
47-6.
60) months month (HR: 1.
94, 95%CI 0.
43 to 8.
79, P=0.
391)
.
Median PFS was not reached in patients with high TMB (95% CI 4 0-not reached), and median PFS in patients with low TMB was 6.
50 months (95% CI 5.
78-7.
23) (HR: 0.
451, 95%CI 0.
090- 2.
263)
.

Six (25.
0%) patients experienced grade 3 or 4 adverse events, including elevated transaminases, thrombocytopenia, fatigue, proteinuria, and ileus
.
There were no serious treatment-related adverse events or treatment-related deaths
.

Six (25.
0%) patients experienced grade 3 or 4 adverse events, including elevated transaminases, thrombocytopenia, fatigue, proteinuria, and ileus
.
There were no serious treatment-related adverse events or treatment-related deaths
.

In conclusion, the study shows that Camrelizumab (camrelizumab) combined with apatinib and S1 as the second-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma has significant curative effect and is safe and controllable
.

In conclusion, the study shows that Camrelizumab (camrelizumab) combined with apatinib and S1 as the second-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma has significant curative effect and is safe and controllable
.
Studies have shown that Camrelizumab (camrelizumab) combined with apatinib and S1 as a second-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma has significant efficacy and is safe and controllable
.
Studies have shown that Camrelizumab (camrelizumab) combined with apatinib and S1 as a second-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma has significant efficacy and is safe and controllable
.

Original source:

Original source:

Jing C, Wang J, Zhu M, Bai Z, Zhao B, Zhang J, Yin J, Yang X, Liu Z, Zhang Z, Deng W.
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Cancer Immunol Immunother.
2022 Mar 18.
doi: 10.
1007/s00262-022-03174-9.
Epub ahead of print.
PMID: 35304622.

Jing C, Wang J, Zhu M, Bai Z, Zhao B, Zhang J, Yin J, Yang X, Liu Z, Zhang Z, Deng W.
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Cancer Immunol Immunother.
2022 Mar 18.
doi: 10.
1007/s00262-022-03174-9.
Epub ahead of print.
PMID: 35304622.
Leave a message here